Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677 sales@csnpharm.com    

EGFR

EGFR

Cat. No. Product Name CAS No. Information
CSN23885 ZD-4190 413599-62-9 ZD-4190 is an inhibitor of vascular endothelial cell growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor (EGFR) signalling.
CSN16336 XL647 781613-23-8 XL647 or tesevatinib inhibits EGFR, HER2, VEGFR and EphB4 with potential antineoplastic activity.
CSN21355 AG 528 133550-49-9 Tyrphostin is a potent inhibitor of EGFR protein tyrosine kinase.
CSN20011 Theliatinib 1353644-70-8 Theliatinib is a small molecule epidermal growth factor receptor tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities
CSN20157 Pyrotinib 1269662-73-8 Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor in patients with HER2-Positive metastatic breast cancer
CSN16204 Poziotinib 1092364-38-9 Poziotinib is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively.
CSN19258 PF-06747775 1776112-90-3 PF-06747775 provides potent EGFR activity against the four common mutants exon 19 deletion Del L858R and double mutants T790ML858R and T790MDel selectivity over wild-type EGFR and desirable ADME properties
CSN11666 Pelitinib 257933-82-7 Pelitinib irreversiblly inhibits EGFR with IC50 of 38.5 nM.
CSN12357 PD153035 153436-54-5 PD153035 is EGFR inhibitor with Ki and IC50 of 5.2 pM and 29 pM and could rapidly suppress autophosphorylation of EGFR.
CSN12700 PD153035 HCl   183322-45-4 PD153035 HCl is an reversible inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM.
CSN13923 Osimertinib Mesylate 1421373-66-1 Osimertinib Mesylate is a selective inhibitor of mutant EGFR with IC50s of 12 nM and 1 nM for L858R and L858R/T790M in enzyme assay respectively.
CSN13922 Osimertinib     1421373-65-0 Osimertinib is a potent and selective mutated forms EGFR inhibitor (Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).
CSN15680 OSI-420 183320-51-6 OSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
CSN17738 Olmutinib   1353550-13-6 Olmutinib inhibits EGFR with IC50 values of 9.2 nM and 10 nM in HCC827 (expressing EGFR-del 19) and H1975 (expressing EGFR-L858RT790M) cell respectively. It is a new targeted drug for the treatment of mutation-positive NSCLC.
CSN17827 Mutant EGFR Inhibitor 1421373-62-7 Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor L858R activating mutant the Exonl9 deletion activating mutant and the T790M resistance mutant
CSN21195 Lazertinib 1903008-80-9 Lazertinib is a selective inhibitor of mutant EGFR with lowest activity against EGFR wild type.
CSN11268 Lapatinib 231277-92-2 Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
CSN24173 JND3229 N/A JND3229 is a potent EGFR inhibitor with IC50 values of 5.8nM, 30.5nM and 6.8nM for EGFR(C797S), EGFR (T790M, L858R) and EGFR, respectively.
CSN24731 Idaein chloride 27661-36-5 Idaein chloride is a glycoside derivative of cyanidin, a potent inhibitor of EGFR, used in comparative analysis of anti-EGF activity in cancer cells.
CSN11084 Gefitinib     184475-35-2 Gefitinibis an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively, and interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
CSN22297 Gefitinib-Based PROTAC 3 2230821-27-7 Gefitinib-based PROTAC 3 is a VHL-recruiting PROTAC that induces the degradation of EGFR and EGFR mutants with DC50 of 11.7 nM and 22.3 nM for HCC827 cell (Exon 19 del) and H3255 cell (L858R).
CSN18153 Erlotinib Mesylate 248594-19-6 Erlotinib mesylate is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM.
CSN10931 Erlotinib   183321-74-6 Erlotinib is an EGFR inhibitor with IC50 of 2 nM, > 1000-fold more sensitive for EGFR than human c-Src or v-Abl.
CSN16725 Erlotinib HCl   183319-69-9 Erlotinib HCl is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM.
CSN16199 EGF816 1508250-71-2 EGF816 inhibits mutant EGFR (L858R790M) with Ki of 31 nM irreversibly and selectively.
CSN10745 Daphnetin 486-35-1 Daphnetin is an inhibitor of EGFR, PKA and PKC with IC50 of 7.67 M, 9.33 M and 25.01 M respectively. It derives from plants of the genus Daphne.
CSN13899 Dacomitinib   1110813-31-4 Dacomitinib is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.
CSN15420 Corylifol C 775351-91-2 Corylifol C is a natural product isolated and purified from the seeds of Psoralea corylifolia L., and a potent protein kinase inhibitors (inhibitory concentration 50 values for epidermal growth factor receptor (EGFR) 1.1 and 4.4 10(-6) gmL, respectively).
CSN17871 CO-1686 Hydrobromide 1446700-26-0 CO-1686 hydrobromide is an irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC5021 nM).
CSN13912 CO-1686   1374640-70-6 CO-1686 functions as an irreversible and mutant-selective inhibitor of EGFRL858RT790M and EGFRWT with Ki of 21.5 nM and 303.3 nM respectively.
CSN16222 CL-387785 194423-06-8 CL-387785 irreversibly inhibits EGFR with IC50 of 370 pM and shows inhibition of the functional effects of mutations T790M.
CSN12261 Canertinib 267243-28-7 Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK124.
CSN10535 Canertinib 2HCl 289499-45-2 Canertinib 2HCl, an irreversible quinazoline-based HER family tyrosine kinase inhibitor, inhibits EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM respectively. Phase II.
CSN16872 AZD3759 1626387-80-1 AZD3759 is an inhibitor of EGFR WT EGFR L858R and EGFR exon 19 deletion IC50s values are 03 nM 02 nM and 02 nM respectively
CSN20594 Avitinib   1557267-42-1 Avitinib selectively inhibits EGFR L858RT790M mutant with IC50 of 768 nM It used as antineoplastic drug candidate
CSN20602 Avitinib Maleate   1557268-88-8 Avitinib maleate, the maleate salt form of avitinib, selectively inhibits EGFR L858RT790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate.
CSN16123 AV-412 451492-95-8 AV-412 is an inhibitor of EGFR (IC50 0.5-2 nM), ErbB2 (IC5019 nM), Abl receptor (IC50 41nM), mutant EGFR-L858R (IC500.51 nM) and EGFR-T790M (IC500.79 nM). It also inhibits autophosphorylation of EGFR and ErbB2 with IC50s of 43 nM and 282 nM, respectively.
CSN18835 AST-1306 p-Toluenesulfonic Acid 1050500-29-2 AST-1306 p-toluenesulfonic acid is an irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790ML858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.
CSN16578 AST-1306 897383-62-9 AST-1306 is an irreversible inhibitor of EGFR and ErbB2 with IC50 of 05 nM and 3 nM also effective in mutation EGFR T790ML858R more potent to ErbB2-overexpressing cells 3000-fold selective for ErbB family than other kinases
CSN24709 AG-1557 189290-58-2 AG1557 is a specific EGFR tyrosine kinase inhibitor with pIC50 value of 8.194.
CSN13724 AG-490   133550-30-8 AG-490 is a broad-spectrum inhibitor that has several targets including EGFR (IC50 2 M), ErbB2 (IC50 13.5 M), STAT3 and JAK2.
CSN10228 AG 18   118409-57-7 AG-18 is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 35 M.
CSN12358 AG-1478   153436-53-4 AG-1478 selectively inhibits EGFR with IC50 of 3 nM in cell-free assay.
CSN16035 Afatinib Dimaleate   850140-73-7 Afatinib dimaleate is an irreversible inhibitor of EGFR and HER2, the IC50s for EGFR (wt), EGFR (L858R), EGFR (L858RT790M) and HER2 are 0.5 nM, 0.4 nM, 10 nM and 14 nM respectively.
CSN21992 Lifirafenib 1446090-79-4
<< PREV 1 2 3 NEXT >>